PHASE-II STUDY OF UFT IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG-CANCER
PHASE-II STUDY OF UFT IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG-CANCER
复制标题
DOI：
10.1093/oxfordjournals.jjco.a039130
复制
发表时间：
1986-06-01
影响因子：
2.4
通讯作者：
HOSHI, A
中科院分区：
文献类型：
--
作者：
KEICHO, N;SAIJO, N;HOSHI, A
对21例晚期非小细胞肺癌(NSCLC)患者进行了UFT(尿嘧啶和替加氟的混合物；尿嘧啶和替加氟的摩尔比=4)的II期研究。口服UFT 400 mg/m2/d，连续4周以上。在接受适当治疗的16名患者中，1名(6.3%)表现出部分反应。毒性反应包括轻微的骨髓抑制、食欲不振、恶心、呕吐和上腹痛。胃肠道毒性耐受性良好。考虑到UFT的不良反应和轻微的毒性，对于没有接受过治疗的患者，有必要对大剂量UFT进行进一步的II期研究。
A phase II study of UFT (a mixture of uracil and tegafur; molar ratio of uracil to tegafur = 4) was undertaken in 21 patients with advanced non-small cell lung cancer (NSCLC). UFT was administered orally at a dose of 400 mg/m2 every day, for more than four weeks. Of 16 adequately treated patients, one (6.3%) showed a partial response. Toxic effects included minimal myelosuppression, anorexia, nausea, vomiting and epigastralgia. Gastrointestinal toxicity was well tolerated. Considering the poor response and mild toxicity, a further phase II study of higher-dose UFT is necessary for patients without prior therapy.